Update: Patient Access Solutions, Hestia Insight, and US Stem Cell to Form Business Consortium
Patient Access Solutions, Inc. (OTC PINK: PASO) has announced a partnership with Hestia Insight and US Stem Cell to form a consortium aimed at treating anxiety and depression. These conditions significantly impact millions in the U.S., with over 40 million adults affected by anxiety and around 19 million by depression. The consortium will utilize Transcranial Magnetic Stimulation (TMS) to enhance brain function. This initiative aligns with a growing healthcare market, projected to reach $11,909 billion by 2022, reflecting a CAGR of 8.9%.
- Formation of a consortium with Hestia Insight and US Stem Cell to address mental health disorders.
- Focus on innovative treatment technologies such as Transcranial Magnetic Stimulation (TMS).
- Potential access to a large market of individuals suffering from anxiety and depression.
- None.
COMMACK, NY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Patient Access Solutions, Inc. (OTC PINK: PASO), a provider of technology and management solutions for the healthcare and financial industries, has announced today that Patient Access Solutions, (PASO) Hestia Insight through its subsidiary Hestia Health, and US Stem Cell will form a Consortium business model for the treatment of individuals with anxiety and depression.
Anxiety disorders affect 40 million adults and one in eight children in the United States. They interfere with daily functioning and often lead to depression, substance abuse, suicide attempts and other disorders. Depressive disorders affect about 19 million American adults. More than 50 percent of people diagnosed with depression also have an anxiety disorder. Coexisting anxiety and depression account for the most disabling mental health disorders in the United States.
We are coming out of a difficult period, with the COVID-19 pandemic, and we believe there are many innovative technologies that should be introduced in the healthcare industry and commercialized. Using Trancranial Magnetic Stimulation (TMS) will optimize the brain function. In recent years, the team has demonstrated that the results from treatment can lead to remarkable clinical improvements in many neuropsychiatric disorders.
Hestia Health, US Stem Cell, and Patient Access Solutions will provide the facility locations and all business narratives including funding/financing, branding, patient awareness campaigns, licensing, facility build outs, and billing.
The global healthcare market reached a value of nearly
About Patient Access Solutions Inc.(www.pashealth.com)
Patient Access Solutions Inc. (PASHealth) is a Healthcare Solutions company which has created a formidable array of technology, management resources and allies to enable it to become an agent of radical change in what has traditionally been a slowly evolving healthcare environment. For more information about the services and products of Patient Access Solutions, please visit our website at www.pashealth.com.
About Hestia Insight Inc.: (www.hestiainsight.com) Hestia Insight Inc. is an advisory Company focused primarily on the great Healthcare and Biotech sectors. It also provides seed capital and mezzanine financing to its clients. Hestia Insight will make strategic acquisitions and mergers or joint ventures with emerging growth companies with intellectual properties. It provides sales and marketing guidance and capital market advice to increase the success of its clients.
About US Stem Cell Inc. (us-semcell.com) is an emerging leader in the regenerative medicine and cellular therapy industry specializing in physician training and certification, as well as veterinary applications, and management of cellular therapy clinics. To management's knowledge, U.S. Stem Cell has completed more clinical treatments than any other cellular therapy company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous cell therapies worldwide.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things, the following: general economic and business conditions; competition; unexpected changes in technologies and technological advances; ability to commercialize and manufacture products; results of experimental studies; research and development activities; changes in, or failure to comply with, governmental regulations; and the ability to obtain adequate financing in the future. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of Patient Access Solutions Inc. Securities and Exchange Commission filings available at http://www.sec.gov.
info@pashealth.com
FAQ
What is the recent announcement from Patient Access Solutions (PASO)?
How will PASO's new consortium impact anxiety and depression treatment?
What is the estimated market value for the healthcare industry related to PASO's announcement?
What mental health conditions are being addressed by PASO's consortium?
